Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $12.9091.

Several equities analysts have recently weighed in on CERT shares. KeyCorp lifted their target price on shares of Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. BMO Capital Markets initiated coverage on shares of Certara in a research note on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price objective for the company. Rothschild Redb upgraded Certara to a “strong-buy” rating in a research report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 22nd. Finally, Redburn Partners set a $10.00 price objective on Certara in a research note on Friday, November 21st.

Hedge Funds Weigh In On Certara

A number of large investors have recently modified their holdings of CERT. Associated Banc Corp boosted its holdings in Certara by 9.7% in the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Certara by 2.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock worth $535,000 after purchasing an additional 1,136 shares during the period. Versant Capital Management Inc raised its position in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after buying an additional 1,153 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Finally, ANTIPODES PARTNERS Ltd grew its position in Certara by 22.5% during the second quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after buying an additional 1,223 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Performance

NASDAQ:CERT opened at $8.89 on Wednesday. Certara has a 1 year low of $8.02 and a 1 year high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The business has a fifty day simple moving average of $9.72 and a two-hundred day simple moving average of $10.67. The company has a market capitalization of $1.42 billion, a P/E ratio of 127.00 and a beta of 1.46.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The company had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. During the same quarter in the prior year, the company earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts expect that Certara will post 0.28 earnings per share for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.